Thalassemia - A Comprehensive Review

Definition & Overview

• Robbins, Cotran & Kumar Pathologic Basis of Disease notes that thalassemia is "among the most common inherited disorders of humans."
• Globally, ~1-5% of the world's population carries a thalassemia mutation; approximately 40,000 β-thalassemia patients are born yearly.
• Endemic regions include the Mediterranean basin, Middle East, tropical Africa, the Indian subcontinent, and Southeast Asia - all regions where malaria is or was endemic (heterozygotes are protected from severe P. falciparum malaria).

Genetics & Molecular Basis

Globin Gene Loci

β-Thalassemia Mutations

• β⁰ mutations: Complete absence of β-globin synthesis (nonsense mutations, frameshifts, splice junction defects)
• β⁺ mutations: Reduced but detectable β-globin synthesis (promoter mutations, mild splice site mutations, poly-A signal mutations)

1. Promoter element mutations → mild β⁺ thalassemia
2. Exon-intron splice junction mutations → β⁰ and β⁺
3. Alternative splice sites introduced into introns/exons → usually β⁺
4. 3' polyadenylation signal mutations → mild/silent β⁺
5. Initiation codon mutations → β⁰
6. Nonsense mutations / frameshift mutations → β⁰ with truncated unstable mRNA

α-Thalassemia Mutations

Classification

β-Thalassemia

α-Thalassemia

Pathophysiology

β-Thalassemia Pathophysiology

1. Membrane lipid oxidation and damage of erythroid precursors
2. Ineffective erythropoiesis (intramedullary destruction of erythroid precursors) - the dominant mechanism of anemia
3. Hemolysis - reduced deformability and phosphatidylserine exposure cause extra- and intravascular hemolysis of those erythrocytes that do enter circulation

• Severe anemia → massive compensatory erythroid hyperplasia
• Bone marrow expansion → bony deformities (frontal bossing, "crew-cut" skull on X-ray, maxillary hypertrophy giving "chipmunk facies")
• Hepatosplenomegaly (extramedullary hematopoiesis + RBC trapping)
• Iron accumulation in liver, heart, and endocrine organs (from both transfusions and increased GI absorption driven by ineffective erythropoiesis suppressing hepcidin)
• Pulmonary hypertension and thromboembolic disease

α-Thalassemia Pathophysiology

• Excess β-chains form β₄ tetramers = Hemoglobin H (HbH)
• Excess γ-chains form γ₄ tetramers = Hemoglobin Bart's (Hb Bart)

Clinical Features

β-Thalassemia Major (Cooley's Anemia)

• Severe microcytic hypochromic anemia (Hgb often <5 g/dL without transfusion)
• Marked anisopoikilocytosis, target cells, teardrop cells, nucleated RBCs
• Elevated reticulocytes (though erythropoiesis is ineffective overall)

• Failure to thrive, pallor, jaundice
• Massive hepatosplenomegaly (extramedullary hematopoiesis)
• Skeletal deformities: frontal bossing, "chipmunk facies" (maxillary overgrowth), crew-cut skull X-ray appearance, osteoporosis
• Growth retardation and delayed puberty (endocrine iron deposition)
• Gallstones (pigment stones from chronic hemolysis)

• Cardiac failure / arrhythmias (most common cause of death)
• Hepatic cirrhosis
• Diabetes mellitus (pancreatic iron)
• Hypogonadism, hypothyroidism, hypoparathyroidism, adrenal insufficiency
• Skin bronzing

β-Thalassemia Intermedia

• Symptomatic anemia (Hgb 7-10 g/dL) but may not require regular transfusions
• Milder skeletal changes; splenomegaly present
• Iron overload still occurs from increased GI absorption
• Normal or late puberty; usually fertile

β-Thalassemia Minor (Trait)

• Usually asymptomatic
• Mild microcytic hypochromic anemia (Hgb rarely < 10 g/dL)
• Elevated RBC count (microcytosis without significant anemia)
• Clinically important only for genetic counseling

HbH Disease (3-gene α-thalassemia)

• Moderate hemolytic anemia (Hgb ~8-9 g/dL)
• Splenomegaly
• Hemolytic crises with infections or oxidant drugs
• Does not usually require regular transfusion
• Rarely transfusion-dependent

Hb Bart's Hydrops Fetalis (4-gene α-thalassemia)

• Stillbirth or death shortly after birth
• Massive hydrops, severe anemia
• Associated with maternal complications (pre-eclampsia, difficult delivery)

Investigations

1. Complete Blood Count (CBC)

• Microcytic hypochromic anemia: low MCV (often <70 fL), low MCH
• Elevated RBC count (in thalassemia trait - distinguishes from iron deficiency)
• Mentzer Index: MCV/RBC count - <13 suggests thalassemia, >13 suggests iron deficiency

2. Peripheral Blood Smear

• Target cells, teardrops, anisopoikilocytosis
• Nucleated RBCs in severe disease
• Basophilic stippling
• HbH inclusions (Heinz bodies-like) in HbH disease (with brilliant cresyl blue stain)

3. Hemoglobin Electrophoresis / HPLC (High-Performance Liquid Chromatography)

• β-thalassemia minor: ↑ HbA₂ (>3.5%, often 4-7%) ± mild ↑ HbF - diagnostic hallmark
• β-thalassemia major: absent or markedly reduced HbA; predominantly HbF (may be >90%)
• HbH disease: HbH band (β₄) on electrophoresis
• Silent α-carrier: usually normal electrophoresis
• β-thalassemia - after recognizing microcytic hypochromic indices and excluding iron deficiency, elevated HbA₂ on HPLC confirms diagnosis

4. Iron Studies

• Serum ferritin, serum iron, TIBC, transferrin saturation
• Important to exclude iron deficiency (which can mask elevated HbA₂) and to monitor iron overload in transfused patients
• Chelation indicated when ferritin consistently >1000 ng/mL

5. Molecular / DNA Analysis

• Definitive diagnosis especially for α-thalassemia (requires gene copy number analysis - multiplex ligation-dependent probe amplification [MLPA] or gap-PCR)
• Identifies specific mutations for genetic counseling and prenatal diagnosis

• 500 unique thalassemia-causing mutations catalogued

6. Imaging

• Skull X-ray: "hair-on-end" or "crew-cut" appearance (marrow expansion through outer table)
• Skeletal survey: generalized osteoporosis, widened medullary cavities
• *MRI (T2)**: gold standard for quantifying cardiac and liver iron overload - critical for managing chelation
• Echocardiography: assess cardiac function in iron-loaded patients
• Ultrasound abdomen: hepatosplenomegaly, gallstones

7. Bone Marrow

• Erythroid hyperplasia
• Usually not required for diagnosis but shows ineffective erythropoiesis

8. Prenatal Diagnosis

• Chorionic villus sampling (CVS) at 10-12 weeks or amniocentesis at 15-18 weeks for DNA analysis
• Cell-free fetal DNA from maternal blood (increasingly available)
• Preimplantation genetic diagnosis (IVF)

Treatment

β-Thalassemia Trait / α-Thalassemia Trait

• No specific treatment required
• Genetic counseling for both partners
• Folic acid supplementation in pregnancy
• Treat concurrent iron deficiency if present (monitor ferritin and transferrin saturation)
• Avoid unnecessary iron supplementation

HbH Disease

• Folic acid 2-5 mg/day
• Avoid oxidant drugs (dapsone, primaquine, sulfonamides)
• Blood transfusions for acute hemolytic crises (with infections)
• Regular monitoring of Hgb and iron stores

β-Thalassemia Major / Transfusion-Dependent Thalassemia (TDT)

1. Regular Red Cell Transfusion

• Goal: maintain pre-transfusion Hgb >9-10 g/dL (Goldman-Cecil: 9-10.5 g/dL)
• Every 2-5 weeks (usually every 3-4 weeks)
• Use leukoreduced, phenotypically matched packed red cells (to minimize alloimmunization and transfusion reactions)
• Suppresses ineffective erythropoiesis and prevents skeletal deformities
• Decision to start lifelong transfusion: based on definitive diagnosis, molecular defects, severity of anemia on repeated measurement, clinical criteria (failure to thrive, bone changes)

2. Iron Chelation Therapy

• Target ferritin <1000 ng/mL; MRI T2* >20 ms (liver), >20 ms (heart) indicates adequate chelation
• Luspatercept (Reblozyl) 1 mg/kg SC every 3 weeks - approved for TDT to reduce transfusion requirements; acts as erythroid maturation agent (TGF-β trap); median time to response 12-24 days

3. Splenectomy

• Considered when annual blood consumption increases progressively (>2 units/month or increasing transfusion requirements)
• Reduces hypersplenism and transfusion requirements
• Risks: post-splenectomy sepsis (vaccinate against pneumococcus, H. influenzae, N. meningitidis at least 2 weeks before surgery), thromboembolic events, pulmonary hypertension
• Avoid in children <5-6 years due to high infection risk
• Lifelong prophylactic penicillin post-splenectomy

4. Folic Acid

• 1-5 mg/day to support erythropoiesis

5. Hematopoietic Stem Cell Transplantation (HSCT)

• Only proven curative therapy
• Best results in young patients (<14 years), Pesaro Class I-II (no hepatomegaly, regular chelation, no portal fibrosis)
• Requires HLA-matched sibling donor (best outcome); matched unrelated donor possible
• Overall cure rate ~80-90% in low-risk patients with matched sibling
• Risks: graft-versus-host disease, graft failure, conditioning regimen toxicity

6. Gene Therapy (Emerging/Approved)

• Betibeglogene autotemcel (Zynteglo): lentiviral vector delivering functional β-globin gene; FDA-approved; can achieve transfusion independence in many TDT patients
• Exagamglogene autotemcel (Casgevy): CRISPR/Cas9 gene editing to reactivate fetal hemoglobin (HbF) by disrupting BCL11A erythroid enhancer; recently approved
• Very costly; curative potential but access limited in low-resource settings

7. Hydroxyurea

• Increases HbF production; more useful in β-thalassemia intermedia/NTDT
• Reduces transfusion requirements in some patients

Monitoring in TDT

• Regular Hgb, ferritin, LFTs, renal function
• Annual/biannual MRI T2* (liver and cardiac iron)
• Echocardiography annually
• Endocrine assessment (glucose, thyroid, parathyroid, pubertal development)
• Ophthalmology and audiology (deferoxamine toxicity screening)

Summary Table: Key Points

Sources

• Harrison's Principles of Internal Medicine, 22nd Ed. (2025), Chapter 103 - Hemoglobinopathies
• Robbins, Cotran & Kumar Pathologic Basis of Disease - Chapter 14
• Robbins & Kumar Basic Pathology - Chapter 10
• Goldman-Cecil Medicine - Thalassemia chapter
• Washington Manual of Medical Therapeutics - Hematology section

Nephrotic Syndrome in Children - Comprehensive Review

Definition

• Proteinuria >40 mg/m²/hour or urinary protein:creatinine ratio >2.0 mg/mg (in children); >3.5 g/24h in adults
• Hypoalbuminemia <2.5 g/dL (serum albumin <3.5 g/dL)
• Generalized edema (anasarca)
• Hyperlipidemia (secondary)

Epidemiology

• Incidence: ~2-7 per 100,000 children per year; prevalence ~16 per 100,000
• Minimal change nephrotic syndrome (MCNS) accounts for ~90% of cases in children <10 years of age and 70-80% of all pediatric NS
• Peak incidence at 2-5 years of age (preschool children); median age 2.5 years
• Male:Female ratio approximately 2:1 in childhood (equalizes in adolescence)
• Steroid-sensitive NS (SSNS): ~80-90% of children; steroid-resistant NS (SRNS): 15-20%

Classification

By Age of Onset

By Etiology

1. Primary (Idiopathic): MCNS, FSGS, Membranous nephropathy (MN), Membranoproliferative GN (MPGN)
2. Secondary: Systemic disease (SLE, HSP/IgAV, amyloidosis, diabetes, HBV, HCV, malaria, HIV, syphilis)
3. Genetic/Hereditary: Mutations in ~30 genes (NPHS1, NPHS2, WT1, PLCE1, LAMB2, CD2AP, TRPC6, ACTN4, etc.)
4. Drug-induced: NSAIDs, captopril, lithium, penicillamine, heroin

By Histopathology (Primary NS)

By Steroid Response (Clinically Most Useful)

• Steroid-Sensitive NS (SSNS): remission within 4-8 weeks of full-dose prednisone
• Steroid-Resistant NS (SRNS): failure to achieve remission after 6-8 weeks of full-dose daily prednisone
• Frequently Relapsing NS (FRNS): ≥2 relapses within 6 months of initial response, OR ≥4 relapses within any 12-month period
• Steroid-Dependent NS (SDNS): relapses during steroid tapering or within 2 weeks of stopping steroids on two consecutive occasions

Pathophysiology

The Glomerular Filtration Barrier

1. Fenestrated glomerular endothelium - size and charge barrier
2. Glomerular basement membrane (GBM) - rich in negatively charged heparan sulfate proteoglycans
3. Podocytes (visceral epithelial cells) with foot processes connected by the slit diaphragm (nephrin, podocin, CD2AP proteins)

Core Mechanism: Proteinuria → Cascade

Glomerular barrier injury (podocyte/slit diaphragm dysfunction)
           ↓
    MASSIVE PROTEINURIA (predominantly albumin)
           ↓
   HYPOALBUMINEMIA (urinary loss > hepatic synthetic capacity + renal catabolism)
           ↓
   ↓ Plasma oncotic pressure
           ↓
   Fluid shifts from intravascular → interstitial space (UNDERFILL theory)
           ↓
   Perceived low effective circulating volume
           ↓
   RAAS activation + ↑ ADH + ↑ sympathetic tone → Na⁺ + H₂O retention
           ↓
         EDEMA

• Underfill theory (classic, especially in MCD): low albumin → ↓ oncotic pressure → plasma volume contracted → secondary Na retention. RAAS activated, renin and aldosterone raised.
• Overfill theory: primary intrinsic renal Na retention (especially in FSGS and membranous nephropathy) → expanded plasma volume → secondary edema. RAAS suppressed.

Pathogenesis of MCD (Most Important in Children)

• Light microscopy: normal glomeruli - hence "minimal change"
• Electron microscopy: diffuse effacement (fusion) of podocyte foot processes - pathognomonic
• Immunofluorescence: negative (no immune complex deposits)
• Pathogenic mechanism: autoantibodies against the slit diaphragm protein nephrin are now recognized in many cases (Goldman-Cecil); T-cell dysfunction with circulating permeability factor (historically postulated); angiopoietin-like-4 (ANGPTL4) secreted by podocytes has been shown to mediate proteinuria in glucocorticoid-sensitive NS

Secondary Consequences

Clinical Features

Presenting Symptoms

• Periorbital edema - classically the first sign; worse in the morning; often mistaken for allergy
• Pitting edema - dependent; lower limbs, scrotum/labia
• Ascites - abdominal distension, discomfort
• Pleural effusions - dyspnea (if large)
• Weight gain (fluid)
• Reduced urine output (concentrated, frothy/foamy urine)
• Pallor, lethargy, anorexia

Signs

• Soft pitting edema - periorbitally, legs, scrotum/labia, sacrum
• Ascites (shifting dullness, fluid thrill)
• Blood pressure - usually normal in MCD; hypertension is atypical and should prompt further investigation
• No hematuria (typically) - microscopic hematuria present in ~20% of MCD; macroscopic hematuria is unusual and suggests nephritic component or FSGS/MN

Features Atypical for MCD (Warranting Biopsy Before Steroids)

1. Age <1 year at presentation (especially <3 months - congenital NS)
2. Macroscopic hematuria
3. Persistent hypertension
4. Hypocomplementemia (↓C3/C4 - suggests MPGN, lupus, post-infectious)
5. Extrarenal features: rash, arthritis, hepatosplenomegaly (secondary causes)
6. Impaired renal function (elevated creatinine)
7. Positive ANA/ANCA/anti-dsDNA
8. Failure to respond to 8 weeks of steroids (SRNS)
9. Strong family history (genetic NS)

Investigations

1. Urine Tests

• Urine dipstick: ≥3+ protein (+++); may show lipiduria
• Spot urine protein:creatinine ratio (PCR): >2 mg/mg (200 mg/mmol) confirms nephrotic-range proteinuria
• 24-hour urine protein: >40 mg/m²/h or >3.5 g/day; largely replaced by spot PCR in children
• Urinalysis with microscopy: oval fat bodies, fatty casts, Maltese cross birefringence; RBC casts absent in pure NS (if present, suggests nephritic component)
• Urine sodium: low in underfill (hypovolemic) state

2. Blood Tests

3. Imaging

• Renal ultrasound: enlarged, echogenic kidneys in NS (non-specific); rules out obstruction, cysts; assesses for thrombosis (Doppler if renal vein thrombosis suspected)
• Chest X-ray: if dyspneic - pleural effusions
• Abdominal X-ray/ultrasound: ascites

4. Kidney Biopsy

• Age <1 year (congenital/infantile NS)
• SRNS (failure after 8 weeks of full-dose steroids)
• Atypical features (macroscopic hematuria, persistent hypertension, hypocomplementemia, extrarenal disease)
• Suspicion of secondary cause
• Frequently relapsing NS being considered for second-line therapy

• MCD: LM normal; EM - diffuse podocyte foot process effacement; IF - negative
• FSGS: LM - focal (<50% glomeruli) and segmental sclerosis/hyalinosis; EM - foot process effacement; IF - IgM/C3 in sclerotic segments
• Membranous: LM - GBM thickening, subepithelial "spikes"; EM - subepithelial immune deposits; IF - granular IgG/C3 (PLA2R staining positive in primary MN)
• MPGN: LM - mesangial proliferation + GBM "tram-track" splitting; IF - C3 ± Ig deposits

Management

General Principles

• Confirm diagnosis (urine PCR, serum albumin, lipids)
• Assess for atypical features requiring biopsy
• Educate family on urine dipstick monitoring at home
• Low-salt diet during edema phase
• Restrict fluid if hyponatremic
• Monitor weight daily; input/output chart

1. Corticosteroids - First-Line Treatment

• Prednisolone 60 mg/m²/day (max 60 mg/day) as a single morning dose for 4-6 weeks (daily)
• Then 40 mg/m² on alternate days for 4-6 weeks, then taper over 4-8 weeks
• Total initial treatment duration: minimum 12-16 weeks (longer courses reduce relapse risk - evidence from RCTs)
• KDIGO 2025 recommends extended initial steroid course

• Prednisolone 60 mg/m²/day until urine protein-free for 3 consecutive days
• Then 40 mg/m² on alternate days for 4 weeks, then stop

• Remission: urine protein dipstick trace or negative (or PCR <0.2) for 3 consecutive days
• Relapse: urine protein ≥2+ (or PCR >2) for 3 consecutive days after remission
• SSNS: complete remission within 8 weeks
• SRNS: no remission after 8 weeks of daily high-dose steroids

2. Management of Edema

• Mild edema: salt restriction alone (no added salt diet, ~1-2 g/day in children)
• Moderate-severe edema: Furosemide 1-2 mg/kg/dose oral or IV (loop diuretic)
• Furosemide + spironolactone combination for resistant edema
• IV albumin (20-25%, 0.5-1 g/kg over 2-4 hours) + IV furosemide for severe refractory edema with signs of intravascular volume depletion/hypovolemia - use cautiously (risk of pulmonary edema)
• Avoid vigorous diuresis in hypovolemic patients (risk of AKI, thrombosis)

3. Steroid-Sparing Agents (FRNS/SDNS)

4. Steroid-Resistant NS (SRNS) Management

• Kidney biopsy mandatory (exclude FSGS, MN)
• Genetic testing (NPHS1, NPHS2, WT1 mutations especially in young children)
• CNIs (cyclosporine or tacrolimus) - first-line for SRNS after biopsy
• Pulse IV methylprednisolone (30 mg/kg/dose, max 1 g) may be tried
• Rituximab in some cases
• High-dose prednisone for 4-16 weeks
• Genetic SRNS: no response to immunosuppression; focus on supportive care

5. Congenital NS Management

• Immunosuppression is not recommended (non-responsive)
• Conservative management: Na and fluid restriction, intermittent IV albumin + furosemide
• Hypercaloric diet for growth
• Thyroid hormone replacement (TBG loss)
• Monitor/treat thrombotic episodes
• Aggressive management of infections
• Bilateral nephrectomy + renal replacement therapy (dialysis → transplant) as definitive management

6. Management of Complications

7. ACE Inhibitors/ARBs

• Not typically used for induction of remission in SSNS
• Useful for: SRNS, FSGS, persistent proteinuria, hypertension, renal protection
• Reduce proteinuria and slow progression of CKD
• Monitor potassium and creatinine; avoid if AKI or hypovolemia

Prognosis

Key Summary Points

• In children 1-8 years, MCD is the presumptive diagnosis - empirical steroid therapy without biopsy is standard
• The tetrad = massive proteinuria + hypoalbuminemia + edema + hyperlipidemia
• First-line = prednisolone 60 mg/m²/day × 4-6 weeks, then alternate-day taper
• ~90% of children with MCD are steroid-sensitive
• Biopsy is indicated for atypical features, SRNS, or before second-line therapy
• Complications to watch: spontaneous bacterial peritonitis, thromboembolism, AKI from hypovolemia, steroid toxicity
• KDIGO 2025 is the current guideline for management of nephrotic syndrome in children (PMID: 40254391)

Sources

• Campbell-Walsh-Wein Urology - Pediatric Glomerular Disease chapter
• Robbins, Cotran & Kumar Pathologic Basis of Disease - Nephrotic Syndrome chapter
• NKF Primer on Kidney Diseases, 8th Ed. - Nephrotic Syndrome
• Goldman-Cecil Medicine - Idiopathic Nephrotic Syndrome
• Brenner and Rector's The Kidney - Sodium/fluid retention in NS
• Symptom to Diagnosis, 4th Ed. - Evidence-Based Diagnosis
• KDIGO 2025 Clinical Practice Guideline for Management of Nephrotic Syndrome in Children (PMID: 40254391) - current authoritative guideline